Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
CAMBRIDGE, Mass. & MONTREAL-(BUSINESS WIRE)-Nov 7, 2023-
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing preclinical programs, RP-1664 and RP-3467, a newly designated Pol? inhibitor, on Wednesday, November 15, 2023 at 8:00 a.m. Eastern Time.
Conference Call and Webcast Details:
To access the call, please dial (877) 870-4263 (U.S. and Canada) or (412) 317-0790 (international) at least 10 minutes prior to the start time and ask to be joined to the Repare Therapeutics call. A live webcast will be available in the Investor section of the Company’s website at https://ir.reparerx.com/events-and-presentations/events. A webcast replay will also be archived for at least 30 days.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; RP-3467, a preclinical Pol? inhibitor program; as well as several additional, undisclosed preclinical programs, including RP-1664. For more information, please visit reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
View source version on businesswire.com:https://www.businesswire.com/news/home/20231107600865/en/
CONTACT: Repare:
Steve Forte
Executive Vice-President and Chief Financial Officer
Repare Therapeutics Inc.
investor@reparerx.comInvestors:
Matthew DeYoung
Argot Partners
repare@argotpartners.comMedia:
David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA CANADA
INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH CLINICAL TRIALS OTHER HEALTH
SOURCE: Repare Therapeutics Inc.
Copyright Business Wire 2023.
PUB: 11/07/2023 07:00 AM/DISC: 11/07/2023 07:00 AM
http://www.businesswire.com/news/home/20231107600865/en